160 related articles for article (PubMed ID: 12623190)
1. Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation.
Corrigan OI; Devlin Y; Butler J
Int J Pharm; 2003 Mar; 254(2):147-54. PubMed ID: 12623190
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluations of ketoprofen extended release pellets prepared using powder layering technique in a rotary centrifugal granulator.
Pai R; Kohli K; Jain G; Srivastava B
Arch Pharm Res; 2011 Jul; 34(7):1135-42. PubMed ID: 21811920
[TBL] [Abstract][Full Text] [Related]
3. Drug release from spray layered and coated drug-containing beads: effects of pH and comparison of different dissolution methods.
Sorasuchart W; Wardrop J; Ayres JW
Drug Dev Ind Pharm; 1999 Oct; 25(10):1093-8. PubMed ID: 10529889
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.
Lorier M; Magallanes L; Ibarra M; Guevara N; Vázquez M; Fagiolino P
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):787-793. PubMed ID: 26590950
[TBL] [Abstract][Full Text] [Related]
5. Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems.
Fadda HM; Merchant HA; Arafat BT; Basit AW
Int J Pharm; 2009 Dec; 382(1-2):56-60. PubMed ID: 19666093
[TBL] [Abstract][Full Text] [Related]
6. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Liu F; Shokrollahi H
Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
[TBL] [Abstract][Full Text] [Related]
7. Influence of the physiological variability of fasted gastric pH and tablet retention time on the variability of in vitro dissolution and simulated plasma profiles.
Kovačič NN; Pišlar M; Ilić I; Mrhar A; Bogataj M
Int J Pharm; 2014 Oct; 473(1-2):552-9. PubMed ID: 25064726
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of a new ketoprofen formulation for once-daily oral administration.
Roda A; Sabatini L; Mirasoli M; Baraldini M; Roda E
Int J Pharm; 2002 Jul; 241(1):165-72. PubMed ID: 12086732
[TBL] [Abstract][Full Text] [Related]
9. Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
Al-Gousous J; Amidon GL; Langguth P
Mol Pharm; 2016 Jun; 13(6):1927-36. PubMed ID: 27139040
[TBL] [Abstract][Full Text] [Related]
10. The effect of pH, buffer capacity and ionic strength on quetiapine fumarate release from matrix tablets prepared using two different polymeric blends.
Hamed R; AlJanabi R; Sunoqrot S; Abbas A
Drug Dev Ind Pharm; 2017 Aug; 43(8):1330-1342. PubMed ID: 28402145
[TBL] [Abstract][Full Text] [Related]
11. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products.
Liu F; Merchant HA; Kulkarni RP; Alkademi M; Basit AW
Eur J Pharm Biopharm; 2011 May; 78(1):151-7. PubMed ID: 21255647
[TBL] [Abstract][Full Text] [Related]
12. Analysis of flurbiprofen, ketoprofen and etodolac enantiomers by pre-column derivatization RP-HPLC and application to drug-protein binding in human plasma.
Jin YX; Tang YH; Zeng S
J Pharm Biomed Anal; 2008 Apr; 46(5):953-8. PubMed ID: 18329215
[TBL] [Abstract][Full Text] [Related]
13. Correlation between the transdermal permeation of ketoprofen and its solubility in mixtures of a pH 6.5 phosphate buffer and various solvents.
Ceschel GC; Maffei P; Lombardi Borgia S
Drug Deliv; 2002; 9(1):39-45. PubMed ID: 11839207
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the utility of an in vitro release test for optimizing semisolid dosage forms.
Proniuk S; Dixon SE; Blanchard J
Pharm Dev Technol; 2001 Aug; 6(3):469-76. PubMed ID: 11485188
[TBL] [Abstract][Full Text] [Related]
15. KINETICS STUDY ON KETOPROFEN RELEASE FROM MINI TABLETS AND MULTI-COMPARTMENT SYSTEMS.
Stawarski T; Sieradzki E; Gałecka E; Binek K
Acta Pol Pharm; 2016; 73(3):731-7. PubMed ID: 27476291
[TBL] [Abstract][Full Text] [Related]
16. Physiological parameters of the gastrointestinal fluid impact the dissolution behavior of the BCS class IIa drug valsartan.
Hamed R
Pharm Dev Technol; 2018 Dec; 23(10):1168-1176. PubMed ID: 30320540
[TBL] [Abstract][Full Text] [Related]
17. In vitro release of ketoprofen suppositories using the USP basket and the flow-through cell dissolution methods.
Medina JR; Padilla AR; Hurtado M; Cortés AR; Domínguez-Ramírez AM
Pak J Pharm Sci; 2014 May; 27(3):453-8. PubMed ID: 24811800
[TBL] [Abstract][Full Text] [Related]
18. Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets.
Karkossa F; Klein S
J Pharm Pharmacol; 2017 Oct; 69(10):1327-1340. PubMed ID: 28703304
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of ketoprofen bioavailability by formation of microsponge tablets.
Comoglu T; Savaşer A; Ozkan Y; Gönül N; Baykara T
Pharmazie; 2007 Jan; 62(1):51-4. PubMed ID: 17294814
[TBL] [Abstract][Full Text] [Related]
20. The Influence of Simulated Fasted Gastrointestinal pH Profiles on Diclofenac Sodium Dissolution in a Glass-Bead Flow-Through System.
Felicijan T; Pišlar M; Vene K; Bogataj M
AAPS PharmSciTech; 2018 Oct; 19(7):2875-2884. PubMed ID: 30151730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
